U
uniQure N.V. (QURE)
NMS – Real vaqt narxi. Valyuta: USD
29.10
+1.46 (5.28%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
29.10
+1.46 (5.28%)
Yopilishda: May 12, 2026, 4:00 PM EDT
uniQure N.V. Qo'shma Shtatlarda kam uchraydigan va boshqa og'ir kasalliklardan aziyat chekayotgan bemorlar uchun davolash usullarini ishlab chiqadi. Kompaniya GEMGENIXni taklif qiladi, bu gemofiliya B bilan yashayotgan odamlarga IX omilni ishlab chiqarish imkonini beradi, bu esa qon ketishi xavfini kamaytirishi mumkin. Kompaniyaning asosiy mahsulot nomzodi AMT-130, gen terapiyasi nomzodi bo'lib, Xantington kasalligini davolash uchun I/II bosqich klinik tadqiqotlarida. Kompaniya, shuningdek, AMT-260ni ishlab chiqmoqda, bu medial temporal lob epilepsiyasini davolash uchun I/IIa bosqich klinik sinovida; AMT-162, bu superoksid dismutaza fermenti bilan bog'liq amiotrofik lateral sklerozni davolash uchun I/IIa bosqich klinik sinovida; va AMT-191, bu Fabri kasalligini davolash uchun I/IIa bosqich klinik sinovida bo'lgan tadqiqot gen terapiyasi nomzodi. U SOD-1dagi mutatsiyalar keltirib chiqaradigan ALS uchun intratekal yuboriladigan tadqiqot gen terapiyasini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Apic Bio bilan litsenziyalash shartnomasiga ega; va CLS Bhering bilan ishlab chiqish va tijoriy ta'minot shartnomasiga ega. uniQure N.V. 1998 yilda tashkil etilgan va shtab-kvartirasi Niderlandiyaning Amsterdam shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer |
| Ms. Chiara Elizabeth Russo | Senior Director of Investor Relations |
| Ms. Erin Boyer | Chief People & Culture Officer |
| Ms. Kylie O'Keefe | Chief Customer & Strategy Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | 10-Q | qure-20260331x10q.htm |
| 2026-04-30 | 8-K | qure-20260430x8k.htm |
| 2026-04-27 | DEFA14A | qure-20260427xdefa14a.htm |
| 2026-04-27 | DEF 14A | qure-20260610xdef14a.htm |
| 2026-04-27 | ARS | qure-20251231xars.pdf |
| 2026-04-16 | PRE 14A | qure-20260610xpre14a.htm |
| 2026-03-02 | 8-K | qure-20260302x8k.htm |
| 2026-03-02 | 10-K | qure-20251231x10k.htm |
| 2026-01-13 | 8-K | qure-20260113x8k.htm |
| 2026-01-09 | 8-K | qure-20260109x8k.htm |